Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 19;19(1):e0297146.
doi: 10.1371/journal.pone.0297146. eCollection 2024.

Evaluating deep learning-based melanoma classification using immunohistochemistry and routine histology: A three center study

Affiliations

Evaluating deep learning-based melanoma classification using immunohistochemistry and routine histology: A three center study

Christoph Wies et al. PLoS One. .

Abstract

Pathologists routinely use immunohistochemical (IHC)-stained tissue slides against MelanA in addition to hematoxylin and eosin (H&E)-stained slides to improve their accuracy in diagnosing melanomas. The use of diagnostic Deep Learning (DL)-based support systems for automated examination of tissue morphology and cellular composition has been well studied in standard H&E-stained tissue slides. In contrast, there are few studies that analyze IHC slides using DL. Therefore, we investigated the separate and joint performance of ResNets trained on MelanA and corresponding H&E-stained slides. The MelanA classifier achieved an area under receiver operating characteristics curve (AUROC) of 0.82 and 0.74 on out of distribution (OOD)-datasets, similar to the H&E-based benchmark classification of 0.81 and 0.75, respectively. A combined classifier using MelanA and H&E achieved AUROCs of 0.85 and 0.81 on the OOD datasets. DL MelanA-based assistance systems show the same performance as the benchmark H&E classification and may be improved by multi stain classification to assist pathologists in their clinical routine.

PubMed Disclaimer

Conflict of interest statement

TJB would like to disclose that he is the owner of Smart Health Heidelberg GmbH (Handschuhsheimer Landstr. 9/1, 69120 Heidelberg, Germany) which develops mobile apps, outside of the submitted work. SHo reports clinical trial support from Almirall and speaker’s honoraria from Almirall, UCB and AbbVie and has received travel support from the following companies: UCB, Janssen Cilag, Almirall, Novartis, Lilly, LEO Pharma and AbbVie outside the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Schematic diagram of the different models.
The red box shows the pipeline for MelanA-stained WSIs and the purple box the pipeline for H&E-stained WSIs. We tessellated MelanA-stained WSIs corresponding to different magnifications and trained individual models on each tile size. The class probabilities for each tile were predicted and aggregated into a slide score by averaging all tile scores. For the H&E-based model we proceeded in the same way.
Fig 2
Fig 2. ROC plots by data modality with corresponding AUROC values.
The different subplots show results for the individual evolved models: A: MelanA-based performance B: H&E-based performance taking all magnifications into account C: combined model using H&E as well as MelanA by aggregating the individual scores. The different colors of the ROC curves show from which data source site the results come: Red: internal results (Dresden), Blue: external results (Erlangen), Purple: external results (Naples).

Similar articles

Cited by

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021. May;71(3):209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Saginala K, Barsouk A, Aluru JS, Rawla P, Barsouk A. Epidemiology of Melanoma. Med Sci. 2021. Oct 20;9(4):63. doi: 10.3390/medsci9040063 - DOI - PMC - PubMed
    1. Elmore JG, Barnhill RL, Elder DE, Longton GM, Pepe MS, Reisch LM, et al. Pathologists’ diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. BMJ. 2017. Jun 28;357:j2813. doi: 10.1136/bmj.j2813 - DOI - PMC - PubMed
    1. Niebling MG, Haydu LE, Karim RZ, Thompson JF, Scolyer RA. Pathology review significantly affects diagnosis and treatment of melanoma patients: an analysis of 5011 patients treated at a melanoma treatment center. Ann Surg Oncol. 2014. Jul;21(7):2245–51. doi: 10.1245/s10434-014-3682-x - DOI - PubMed
    1. Höhn J, Krieghoff-Henning E, Jutzi TB, von Kalle C, Utikal JS, Meier F, et al. Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification. Eur J Cancer Oxf Engl 1990. 2021. May;149:94–101. doi: 10.1016/j.ejca.2021.02.032 - DOI - PubMed